Metabolic syndrome among psychiatric outpatients with mood and anxiety disorders

BMC Psychiatry

Chun-Lin Chu¹  Nan-Wen Yu¹  Mei-Chun Hsiao²  Chia-Yih Liu²  Ching-I Hung² 

[1] Department of Psychiatry, Chang-Gung Memorial Hospital at Linkou, 5 Fu-Shing St, Kweishan, Taoyuan 333, Taiwan;Chang-Gung University School of Medicine, Taoyuan, Taiwan

关键词: Metabolic syndrome;    Anxiety;    Depression;    Bipolar disorder;   

Others  :  793891
DOI  :  10.1186/1471-244X-14-185

 received in 2013-07-01, accepted in 2014-06-17,  发布年份 2014

【 摘 要 】

Background

Few studies have simultaneously compared the impacts of pharmacotherapy and mental diagnoses on metabolic syndrome (MetS) among psychiatric outpatients with mood and anxiety disorders. This study aimed to investigate the impacts of pharmacotherapy and mental diagnoses on MetS and the prevalence of MetS among these patients.

Methods

Two-hundred and twenty-nine outpatients (men/women = 85/144) were enrolled from 1147 outpatients with mood and anxiety disorders by systematic sampling. Psychiatric disorders and MetS were diagnosed using the Structured Clinical Interview for DSM-IV-TR and the new International Diabetics Federation definition, respectively. The numbers of antipsychotics, mood stabilizers, and antidepressants being taken were recorded. Logistic regression was used to investigate the impacts of pharmacotherapy and psychiatric diagnoses on MetS.

Results

Among 229 subjects, 51 (22.3%) fulfilled the criteria for MetS. The prevalence of MetS was highest in the bipolar I disorder (46.7%) patients, followed by bipolar II disorder (25.0%), major depressive disorder (22.0%), anxiety-only disorders (16.7%), and no mood and/or anxiety disorders (14.3%). The percentages of MetS among the five categories were correlated with those of the patients being treated with antipsychotics and mood stabilizers. Use of antipsychotics and/or mood stabilizers independently predicted a higher risk of MetS after controlling for demographic variables and psychiatric diagnoses. When adding body mass index (BMI) as an independent variable in the regression model, BMI became the most significant factor to predict MetS.

Conclusion

BMI was found to be an important factor related to MetS. Pharmacotherapy might be one of underlying causes of elevated BMI. The interactions among MetS, BMI, pharmacotherapy, and psychiatric diagnoses might need further research.

【 授权许可】

   
2014 Hung et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Alberti KG, Zimmet P, Shaw J: Metabolic syndrome-a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006, 23:469-480.
• [2]Wang Y, Yu Q, Chen Y, Cao F: Pathophysiology and therapeutics of cardiovascular disease in metabolic syndrome. Curr Pharm Des 2013, 19:4799-4805.
• [3]Singh RB, Gupta S, Dherange P, De Meester F, Wilczynska A, Alam SE, Pella D, Wilson DW: Metabolic syndrome: a brain disease. Can J Physiol Pharmacol 2012, 90:1171-1183.
• [4]Chang HH, Chou CH, Chen PS, Gean PW, Huang HC, Lin CY, Yang YK, Lu RB: High prevalence of metabolic disturbances in patients with bipolar disorder in Taiwan. J Affect Disord 2009, 117:124-129.
• [5]McElroy SL, Keck PE: Metabolic syndrome in bipolar disorder: a review with a focus on bipolar depression. J Clin Psychiatry 2014, 75:46-61.
• [6]Chadda RK, Ramshankar P, Deb KS, Sood M: Metabolic syndrome in schizophrenia: differences between antipsychotic-naive and treated patients. J Pharmacol Pharmacother 2013, 4:176-186.
• [7]Malhotra N, Kulhara P, Chakrabarti S, Grover S: A prospective, longitudinal study of metabolic syndrome in patients with bipolar disorder and schizophrenia. J Affect Disord 2013, 150:653-658.
• [8]Kim B, Kim SJ, Son JI, Joo YH: Weight change in the acute treatment of bipolar I disorder: a naturalistic observational study of psychiatric inpatients. J Affect Disord 2008, 105:45-52.
• [9]Al-Zoairy R, Ress C, Tschoner A, Kaser S, Ebenbichler C: The effects of psychotropic drugs on the regulation of glucose metabolism. Curr Diabetes Rev 2013, 9:362-370.
• [10]Hasnain M, Vieweg WV: Weight considerations in psychotropic drug prescribing and switching. Postgrad Med 2013, 125:117-129.
• [11]van Winkel R, van Os J, Celic I: Psychiatric diagnosis as an independent risk factor for metabolic disturbances: results from a comprehensive, naturalistic screening program. J Clin Psychiatry 2008, 69:1319-1327.
• [12]Taylor V, MacQueen G: Associations between bipolar disorder and metabolic syndrome: a review. J Clin Psychiatry 2006, 67:1034-1041.
• [13]McIntyre RS, Rasgon NL, Kemp DE, Nguyen HT, Law CW, Taylor VH, Woldeyohannes HO, Alsuwaidan MT, Soczynska JK, Kim B, Lourenco MT, Kahn LS, Goldstein BI: Metabolic syndrome and major depressive disorder: co-occurrence and pathophysiologic overlap. Curr Diab Rep 2009, 9:51-59.
• [14]Viinamaki H, Heiskanen T, Lehto SM, Niskanen L, Koivumaa-Honkanen H, Tolmunen T, Honkalampi K, Saharinen T, Haatainen K, Hintikka J: Association of depressive symptoms and metabolic syndrome in men. Acta Psychiatr Scand 2009, 120:23-29.
• [15]Takeuchi T, Nakao M, Kachi Y, Yano E: Association of metabolic syndrome with atypical features of depression in Japanese people. Psychiatry Clin Neurosci 2013, 67:532-539.
• [16]Kahl KG, Greggersen W, Schweiger U, Cordes J, Balijepalli C, Lösch C, Moebus S: Prevalence of the metabolic syndrome in unipolar major depression. Eur Arch Psychiatry Clin Neurosci 2012, 262:313-320.
• [17]Goldbacher EM, Bromberger J, Matthews KA: Lifetime history of major depression predicts the development of the metabolic syndrome in middle-aged women. Psychosom Med 2009, 71:266-272.
• [18]McIntyre RS, Filteau MJ, Martin L, Patry S, Carvalho A, Cha DS, Barakat M, Miguelez M: Treatment-resistant depression: Definitions, review of the evidence, and algorithmic approach. J Affect Disord 2014, 156:1-7.
• [19]Herva A, Rasanen P, Miettunen J, Timonen M, Läksy K, Veijola J, Laitinen J, Ruokonen A, Joukamaa M: Co-occurrence of metabolic syndrome with depression and anxiety in young adults: the Northern Finland 1966 Birth Cohort Study. Psychosom Med 2006, 68:213-216.
• [20]Hildrum B, Mykletun A, Midthjell K, Ismail K, Dahl AA: No association of depression and anxiety with the metabolic syndrome: the Norwegian HUNT study. Acta Psychiatr Scand 2009, 120:14-22.
• [21]Butnoriene J, Bunevicius A, Norkus A, Bunevicius R: Depression but not anxiety is associated with metabolic syndrome in primary care based community sample. Psychoneuroendocrinology 2014, 40:269-276.
• [22]Carroll D, Phillips AC, Thomas GN, Gale CR, Deary I, Batty GD: Generalized anxiety disorder is associated with metabolic syndrome in the Vietnam experience study. Biol Psychiatry 2009, 66:91-93.
• [23]Albert U, Aguglia A, Chiarle A, Bogetto F, Maina G: Metabolic syndrome and obsessive-compulsive disorder: a naturalistic Italian study. Gen Hosp Psychiatry 2013, 35:154-159.
• [24]First MB, Spitzer RL, Gibbon M, Williams JBW: Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition (SCID-I/P). New York: Biometrics Research, New York State Psychiatric Institute; 2002.
• [25]American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000.
• [26]Hamilton M: Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967, 6:278-296.
• [27]Hung CI, Liu CY, Wang SJ, Yao YC, Yang CH: The cut-off points of the Depression and Somatic Symptoms Scale and the Hospital Anxiety and Depression Scale in detecting non-full remission and a current major depressive episode. Int J Psychiatry Clin Pract 2012, 16:33-40.
• [28]Hung CI, Liu CY, Wang SJ, Juang YY, Yang CH: Somatic symptoms: an important index in predicting the outcome of depression at six-month and two-year follow-up points among outpatients with major depressive disorder. J Affect Disord 2010, 125:134-140.
• [29]Zigmond AS, Snaith RP: The hospital anxiety and depression scale. Acta Psychiatr Scand 1983, 67:361-370.
• [30]Duncan EJ, Woolson SL, Hamer RM, Dunlop BW: Risk of lipid abnormality with haloperidol, olanzapine, quetiapine, and risperidone in a Veterans Affairs population. Int Clin Psychopharmacol 2009, 24:204-213.
• [31]Stahl SM, Mignon L, Meyer JM: Which comes first: atypical antipsychotic treatment or cardiometabolic risk? Acta Psychiatr Scand 2009, 119:171-179.
• [32]Torrent C, Amann B, Sanchez-Moreno J, Colom F, Reinares M, Comes M, Rosa AR, Scott J, Vieta E: Weight gain in bipolar disorder: pharmacological treatment as a contributing factor. Acta Psychiatr Scand 2008, 118:4-18.
• [33]Hwang LC, Bai CH, Chen CJ: Prevalence of obesity and metabolic syndrome in Taiwan. J Formos Med Assoc 2006, 105:626-635.
• [34]Barnes RD, Boeka AG, McKenzie KC, Genao I, Garcia RL, Ellman MS, Ellis PJ, Masheb RM, Grilo CM: Metabolic syndrome in obese patients with binge-eating disorder in primary care clinics: a cross-sectional study. Prim Care Companion CNS Disord 2011., 13(2)
• [35]Blomquist KK, Milsom VA, Barnes RD, Boeka AG, White MA, Masheb RM, Grilo CM: Metabolic syndrome in obese men and women with binge eating disorder: developmental trajectories of eating and weight-related behaviors. Compr Psychiatry 2012, 53:1021-1027.
• [36]Richter N, Juckel G, Assion H-J: Metabolic syndrome: a follow-up study of acute depressive inpatients. Eur Arch Psychiatry Clin Neurosci 2010, 260:41-49.
• [37]Garcia-Portilla MP, Saiz PA, Benabarre A, Sierra P, Perez J, Rodriguez A, Livianos L, Torres P, Bobes J: The prevalence of metabolic syndrome in patients with bipolar disorder. J Affect Disord 2008, 106:197-201.
• [38]Wu RR, Zhao JP, Liu ZN, Zhai JG, Guo XF, Guo WB, Tang JS: Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. Psychopharmacology 2006, 186:572-578.